• Epigenetic Programming in Primary Human T Cells

  2026-10-13

  The cited Nature Biotechnology study presents an all-RNA CRISPRoff/CRISPRon platform for durable, multiplexed gene regulation in primary human T cells. Its findings support the feasibility of combining transient epigenetic programming with targeted genetic engineering in preclinical CAR-T models, while leaving important questions about locus-specific durability, safety, manufacturing, and clinical translation unresolved.

• Sex, Angiotensin II, and Autonomic Blood Pressure Control

  2026-10-13

  Xue, Pamidimukkala, and Hay examined whether male and female mice respond differently to chronic angiotensin II exposure. The study found a substantially larger blood-pressure increase in males, opposite effects of gonadectomy in the two sexes, and evidence for sex-dependent autonomic and baroreflex contributions. These findings are informative for this mouse model but do not establish a universal mechanism of hypertension or document use of Hexamethonium Bromide.

• Nigericin Sodium Salt: Evidence and Scope

  2026-10-12

  Nigericin sodium salt is documented by APExBIO as a potassium ionophore that exchanges K+ and H+ across biological membranes. The available product description supports a conceptual scope involving ion gradients, cytoplasmic pH regulation, platelet aggregation modulation, and lead-ion transport, but no matched paper was provided, so independent evidence for mechanisms, outcomes, or clinical relevance cannot be assessed.

• Mechanical Stress, Autophagy and the Cytoskeleton

  2026-10-12

  The cited study examines how human cells convert compressive mechanical stress into an autophagy response. Its findings support a central role for microfilaments and a supporting role for microtubules, while leaving the molecular signaling pathway and broader applicability unresolved. Ruthenium Red and related calcium-transport claims are separate from the evidence presented in this study.

• Rucaparib and PARP Inhibitor Research: Evidence Context

  2026-10-10

  Rucaparib, also known as AG-014699, is a PARP inhibitor used in research on DNA damage responses, repair vulnerability and cancer biology. This overview separates vendor-described properties from findings in a 2024 hepatocellular carcinoma study, evaluates the evidence for spliceosome-linked PARP inhibitor sensitivity, and defines where conclusions about radiosensitization or therapeutic combinations remain preliminary.

• ECL Western Blotting Substrate: Product Overview

  2026-10-09

  ECL Western Blotting Substrate (SKU K2187) is described by APExBIO as a luminol-based, nonradioactive horseradish peroxidase detection reagent for protein detection by chemiluminescence in Western blot assays. No matched paper evidence was provided, so performance claims remain unverified.

• Dabigatran Etexilate: From Target to Evidence

  2026-10-09

  Dabigatran etexilate is an oral prodrug and direct thrombin inhibitor with a distinctive evidence trail from molecular pharmacology to stroke prevention research. This article provides an interpretation framework for connecting thrombin inhibition, assay readouts, clinical findings, and translational limitations without confusing product characteristics with clinical conclusions.

• Berberine Hydrochloride and the Gut–Bone Axis

  2026-10-08

  A source-grounded overview of berberine research in estrogen-deficiency bone loss, focusing on the reported butyrate–GPR41–tuft-cell mechanism, osteoimmune findings, evidence strength, metabolic research context, and key translational limitations.

• FXR–KLF11 Signaling in Contrast-Induced AKI

  2026-10-08

  A 2026 study identifies an FXR–KLF11 transcriptional axis that protects against contrast-induced acute kidney injury by restraining JAK2/STAT3-associated inflammation and apoptosis. Its combined genetic, cellular, transcriptional, and in vivo evidence supports a mechanistic rationale for FXR-directed prevention, while remaining preclinical and not yet clinically validated.

• Angiotensin 1/2 (5-7): From RAS to Translation

  2026-10-07

  Angiotensin 1/2 (5-7), the H2N-Ile-His-Pro-OH peptide, sits at an important intersection of renin-angiotensin system research, blood pressure biology, and emerging host–virus interaction studies. This thought-leadership analysis examines what recent SARS-CoV-2 spike-binding findings do—and do not—establish, how researchers can frame translational validation, and why analytical definition matters when short angiotensin fragments are compared across models.

• Dinaciclib and the Mechanics of Tissue Boundaries

  2026-10-06

  Dinaciclib (SCH727965) is examined here as a tool for connecting CDK signaling with cell-cycle control, apoptosis, and tissue-interface biology. Grounded in a 2026 Drosophila study, this article separates established product findings from broader hypotheses about cancer research.

• Dabigatran Etexilate: Evidence and Research Context

  2026-10-06

  Dabigatran etexilate is an oral prodrug of the direct thrombin inhibitor dabigatran. This overview examines its thrombin inhibition mechanism, clinical research context, evidence compared with older anticoagulants, conceptual applications, and important limitations in translating clinical findings to laboratory or disease settings.

• Cyclodextrins and TRPV1/TRPA1 Pain Signaling

  2026-10-05

  The 2025 study by Nehr-Majoros and colleagues examines whether cholesterol depletion by cyclodextrin derivatives can reduce nociception driven by TRPV1 and TRPA1 without relying on conventional receptor antagonism. Its mouse, biochemical, and computational evidence supports membrane lipid organization as a potential modulator of peripheral pain and neurogenic inflammation, while leaving important questions about specificity, durability, and clinical translation.

• GPR35–KLF5 Signaling in Epithelial Repair

  2026-10-05

  The reference study identifies a tryptophan–kynurenine–kynurenic acid sensing mechanism in which GPR35 connects mucosal damage signals to KLF5-dependent epithelial repair. Its findings place PI3K–AKT–mTOR signaling, epithelial proliferation, and migration within a proposed repair circuit relevant to ulcerative colitis research, while leaving important questions about model context and clinical transferability.

• Nonivamide: From TRPV1 Biology to Translation

  2026-10-04

  Nonivamide, a capsaicin analog and TRPV1 agonist, offers translational researchers a chemical lens for studying sensory biology, inflammation, and cancer cell growth inhibition. This thought-leadership article connects supplier-reported oncology findings with a 2024 dermatitis study while distinguishing mechanistic evidence from early-stage hypotheses and outlining strategic questions for future validation.

8167 records 4/545 page Previous Next 12345 下5页 Last page